Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
about
How to optimally manage elderly bladder cancer patients?Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial CarcinomaSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.Evaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose.Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder.Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity.Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions.Defining the potential of neoadjuvant chemotherapy use as a quality indicator for bladder cancer care.Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists.Bladder cancer in the elderly.Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy.Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy.Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder.Increasing utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the United States.Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapyPractical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting.Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohortPhase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis.Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practiceFront-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II StudyImpact of renal function on treatment options and outcomes in advanced non-small cell lung cancer.The kidney in oncology.Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma.Urothelial carcinoma management in elderly or unfit patients.Current optimal chemotherapy for advanced urothelial cancer.Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerNeoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.New therapeutic targets in the management of urothelial carcinoma of the bladderPretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.Perioperative chemotherapy for muscle-invasive bladder cancer.Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.Managing muscle-invasive bladder cancer in the elderly.Management of advanced bladder cancer in patients with impaired renal function.Chemotherapy for bladder cancer in patients with impaired renal function.
P2860
Q28076939-BFEC36B7-FD7A-4F53-89B9-A683535258A4Q28084715-9D7802CF-E991-40F4-8EAE-E38F1A7173E4Q30240816-27297CE1-9CA1-427B-AC97-42A948883B6BQ33383126-1B78CB4D-9780-4E4E-AA89-02C246F5030FQ33398722-D3A1F5B1-3CCD-461E-BB2B-4C81D68AF9EEQ33407440-7292DF40-FF61-408E-99D3-BD6FB8AD2B47Q33411962-6972ED29-0F2A-496A-A807-9CD731B0CB0FQ33435967-6AFCD9D4-BD2D-4666-A91F-695F68C0C829Q33662842-B6E36B72-5E37-4AD9-8079-27DA772DC2B2Q33758673-6FE3978A-5443-470C-8A31-88BA82743EA6Q34021124-247AE6A1-9EFA-4489-B3E9-95AFEE1506DFQ34435978-DED341C7-50B0-4958-B829-D7C33F7C2C37Q34479053-A7EE5A5E-833C-4E87-91E6-841A3C4D4FFEQ35076309-2062F32A-4A25-4969-AD45-5D70DCF3989FQ35109085-B0F51970-7F91-4AC1-ADC2-9A14A3F3BC24Q35125750-0B5C6801-C77C-4A2E-806F-6643AAF4C4B0Q35748060-96BD7840-733D-468C-9248-16E2666FF215Q35748071-24334085-EB51-4FF1-BBEF-6893776E0D22Q36143699-3D7CFB68-ABBC-46BD-8999-65CD643F1981Q36474159-418B8942-B8FF-4CC2-9188-D9A402E1D659Q36487162-812DBE6C-3B9C-4890-AEB3-7A57C85A7D72Q36615090-AF9F8C05-40E7-4DA4-AA78-9148305DEE3CQ36631959-5E6406E5-50B4-429A-87E8-77D392863C31Q36631963-D5998677-0D5A-4495-9FF9-879B478B5745Q36689661-8790F12C-499A-4FDE-9D1E-4DC6D979B6A7Q36823770-3ECBCF91-583C-4D22-80CA-785122448B4EQ36900332-4CDA8DB3-397F-4099-A653-768ABD2FE24DQ36945480-A9331A7B-CD51-4237-BBF6-B2BAD33B42A7Q37030514-73D2ACFC-0E5B-4E3F-9587-1A5D950CEBA3Q37038897-C8FE753B-6995-40EB-AFAF-490655D97171Q37053820-4961B58B-7195-4C03-8373-99DF5161AE29Q37128756-31FE562F-152C-42D7-84BB-AA5713BF2526Q37305943-273D7822-C43F-496A-AB25-A45132B6E926Q37378328-FE076504-C7AE-4149-AD6C-320596E593EEQ37472550-84B95380-2381-4647-B528-E68ED78D1C53Q37474079-756BB92A-D0D9-4032-8031-9DA89B7F46C0Q37555069-B7BA3A3C-4692-4E9D-AC0D-4C7BF0986C6BQ37765589-D6B98BE5-B75B-4D51-BDBF-F2ACFC871375Q37894683-0C2F3FA4-3379-45B2-963C-63B2C1B203F1Q37959263-EF2E95A7-5B8B-4964-A46F-CA61DCC5DDC4
P2860
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Impact of renal impairment on ...... lial carcinoma of the bladder.
@en
Impact of renal impairment on ...... lial carcinoma of the bladder.
@nl
type
label
Impact of renal impairment on ...... lial carcinoma of the bladder.
@en
Impact of renal impairment on ...... lial carcinoma of the bladder.
@nl
prefLabel
Impact of renal impairment on ...... lial carcinoma of the bladder.
@en
Impact of renal impairment on ...... lial carcinoma of the bladder.
@nl
P2093
P356
P1433
P1476
Impact of renal impairment on ...... lial carcinoma of the bladder.
@en
P2093
Angel M Serio
Atreya Dash
Guido Dalbagni
Matthew D Galsky
Theresa M Koppie
P304
P356
10.1002/CNCR.22031
P407
P577
2006-08-01T00:00:00Z